The online consultation is now closed. The content found on this page is a snapshot of the live consultation as it was presented to the public and contains the content that was open for submissions during the consultation period.
The purpose of this letter is to provide an opportunity to comment on the proposal to add to Part I of Schedule F to the Food and Drug Regulations six medicinal ingredients: alitretinoin, its salts and derivatives; aripiprazole and its salts; besifloxacin and its salts; doripenem, its salts and derivatives; saxagliptin and its salts; and sevoflurane.
This consultation is open for comment starting June 30, 2011 until September 13, 2011. Please select and read through the link below titled "consultation document". Once read please submit your comments via email, fax or by mail to:
Refer to Project Number: 1658
Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
Health Canada
1600 Scott Street, Holland Cross
Tower 'B', Second Floor
Address Locator: 3102C5
Ottawa, Ontario
K1A 0K9
Telephone: 613-948-4623
Facsimile: 613-941-6458
Interested parties are encouraged to provide comments and suggestions by September 13, 2011.
Health Canada will make the results of this consultation available on this website.
If you have any questions, contact us at Regulatory Affairs.